A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological diseases of ineffective hematopoiesis with a risk for progression to acute myeloid leukemia (AML) [1,2]. More than 80% of individuals with MDS are 65 years old or older at the time of diagnosis [3]; the average age at diagnosis is 67 years old [4]. Anemia and fatigue are common in MDS, and are often managed through red blood cell transfusions. In addition, MDS can transform into AML requiring intensive chemotherapy and prolonged hospital stays of approximately 30 days [5], which can lead to severe toxicities and functional impairments [5 –8]. (Sou...
Source: Leukemia Research - June 7, 2018 Category: Hematology Authors: Ashley Leak Bryant, Sarah W. Drier, Sejin Lee, Antonia V. Bennett Source Type: research
The Real-World Outcomes of Treating Polycythemia Vera: Physician Adherence to Treatment Guidelines
Polycythemia Vera (PV) is a BCR-ABL negative myeloproliferative neoplasm characterized by the proliferation of red blood cells, although white blood cells and platelets are often also elevated. [1] Mutations of Janus Kinase 2 (JAK2), particularly JAK2V617F, are present in 98% of PV patients.[2] The natural history of PV includes progression to myelofibrosis (MF), myelodysplastic syndrome or acute myeloid leukemia (AML) at a rate of 1.3 progressions per 100 patient-years.[3] Untreated life expectancy is 6 to 18 months.[1] Lifespan is extended with treatment, although mortality is still about 1.6 times higher than age-matche...
Source: Leukemia Research - June 4, 2018 Category: Hematology Authors: Nicholas L. Jackson Chornenki, Chatree Chai-Adisaksopha, Darryl P. Leong, Deborah M. Siegal, Christopher M. Hillis Tags: Research paper Source Type: research
Constitutional mutations of the CHEK2 gene are a risk factor for MDS, but not for de novo AML
The CHEK2 is a tumor suppressor gene (locus 22q12.1), that encodes the cell cycle G2 checkpoint kinase, which plays a key role in cell response to DNA damage (DDR) induced by replication stress and double strand DNA breaks. After ATM (ataxia telangiectasia mutated gene) - mediated activation, CHEK2 can phosphorylate several substrates involved in cell cycle regulation, DNA repair (e.g. BRCA1-breast cancer susceptibility gene 1), TP53 signaling, as well as induction and regulation of apoptosis [1,2]. (Source: Leukemia Research)
Source: Leukemia Research - June 3, 2018 Category: Hematology Authors: Hanna Janiszewska, Aneta B ąk, Katarzyna Skonieczka, Anna Jaśkowiec, Marek Kiełbiński, Anna Jachalska, Maria Czyżewska, Bożena Jaźwiec, Małgorzata Kuliszkiewicz-Janus, Jarosław Czyż, Kazimierz Kuliczkowski, Olga Haus Tags: Research paper Source Type: research
Editorial Board
(Source: Leukemia Research)
Source: Leukemia Research - June 1, 2018 Category: Hematology Source Type: research
Retraction notice to "Arsenic Trioxide Inhibits Proliferation and Induced apoptosis of Leukemia Stem Cells with Drug Resistance " [LR 69 (2018) 66-71]
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). (Source: Leukemia Research)
Source: Leukemia Research - June 1, 2018 Category: Hematology Authors: Chunxia Liu, Hulai Wei, Xiaojian Yao, Bei Liu, Yaming Xi, Li Zhao Source Type: research
The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia
(Source: Leukemia Research)
Source: Leukemia Research - June 1, 2018 Category: Hematology Authors: Vera Vulaj, Anthony J. Perissinotti, James R. Uebel, Victoria R. Nachar, Gianni B. Scappaticci, Ashley Crouch, Dale L. Bixby, Patrick W. Burke, Ivan P. Maillard, Moshe Talpaz, Bernard L. Marini Source Type: research
Characterization of Chronic Myelomonocytic Leukemia with TP53 mutations
Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm with hybrid features of a myeloproliferative neoplasm (MPN) and a myelodysplastic syndrome (MDS). Based on the blast count, CMML cases can be classified into three categories: CMML-0, CMML-1, and CMML-2; and based on the white blood cell (WBC) count, CMML cases can be subdivided into two groups: dysplastic CMML and proliferative CMML [1]. (Source: Leukemia Research)
Source: Leukemia Research - May 31, 2018 Category: Hematology Authors: Wei Wang, Mark J. Routbort, Sanam Loghavi, Zhenya Tang, L. Jeffrey Medeiros, Sa A. Wang Tags: Letter to the Editor Source Type: research
Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A
(Source: Leukemia Research)
Source: Leukemia Research - May 29, 2018 Category: Hematology Authors: C. Kelaidi, T. Braun, R. Arana, A. Marceau-Renaut, G. Lazarian, J. Soret, S. Cereja, R. Letestu, V. Eclache, D. Lusina, F. Baran-Marszak, L. Ades, C. Preudhomme, A. Martin, P. Fenaux, C. Gardin Source Type: research
Circular RNA expression profiles are significantly altered in mice bone marrow stromal cells after total body irradiation
(Source: Leukemia Research)
Source: Leukemia Research - May 28, 2018 Category: Hematology Authors: Junhua Zhang, Jing Jiang, Rong Huang, Yanjie Wang, Xinmin Nie, Rong Gui Source Type: research
Expression of PD-1 on peripheral blood Treg cells is related to the diagnosis, prognosis and treatment of T cell non-Hodgkin lymphoma
(Source: Leukemia Research)
Source: Leukemia Research - May 24, 2018 Category: Hematology Authors: Mengxuan Zuo, Haorui Shen, Jingjing Yin, Wei Wang, Yan Zhang, Dao-Bin Zhou, Wei Zhang Tags: Research paper Source Type: research
Outcomes and Predictors of Survival in Blast Phase Myeloproliferative Neoplasms
(Source: Leukemia Research)
Source: Leukemia Research - May 21, 2018 Category: Hematology Authors: Guido Lancman, Andrew Brunner, Ronald Hoffman, John Mascarenhas, Gabriela Hobbs Tags: Research paper Source Type: research
Heterogeneity of intrahepatic iron deposition in transfusion-dependent iron overload patients with hematological malignancies
(Source: Leukemia Research)
Source: Leukemia Research - May 21, 2018 Category: Hematology Authors: Hironori Kobayashi, Norihiko Yoshimura, Shun Uemura, Takayuki Katagiri, Tomoyuki Tanaka, Takashi Ushiki, Kyoko Fuse, Yasuhiko Shibasaki, Miwako Narita, Hirohito Sone, Masayoshi Masuko Tags: Correspondence Source Type: research
Over expression of circulating miR-155 predicts prognosis in diffuse large B-cell lymphoma
(Source: Leukemia Research)
Source: Leukemia Research - May 21, 2018 Category: Hematology Authors: Mohammad Ahmadvand, Mahsa Eskandari, Hossein Pashaiefar, Marjan Yaghmaie, Saba Manoochehrabadi, Golnaz Khakpour, Fatemeh Sheikhsaran, Mostafa Montazer Zohour Tags: Brief communication Source Type: research
Identification of new phosphorylation sites of CD23 in B-cells of patients with chronic lymphocytic leukemia
(Source: Leukemia Research)
Source: Leukemia Research - May 9, 2018 Category: Hematology Authors: Martina Ma ďarová, Rastislav Mucha, Stanislav Hresko, Zuzana Makarová, Zuzana Gdovinová, Jarmila Szilasiová, Marianna Vitková, Tomáš Guman, Natalia Štecová, Tomas Dobransky Tags: Research paper Source Type: research
The division of chronic myelomonocytic leukemia (cmml)-1 into cmml-0 and cmml-1 according to 2016 world health organization (who) classification has no impact in outcome in a large series of patients from the spanish group of mds
(Source: Leukemia Research)
Source: Leukemia Research - May 9, 2018 Category: Hematology Authors: Blanca Xicoy, Ana Triguero, Esperanza Such, Olga Garc ía, María-José Jiménez, Montserrat Arnán, Teresa Bernal, Marina Diaz-Beya, David Valcárcel, Carme Pedro, Fernando Ramos, María-Luz Amigo, Rosa Collado, Laura Palomo, María-Teresa Ardanaz, Marí Tags: Letter to the Editor Source Type: research
